Physician profile
Abby E Hubbard
NPI 1316357643
$4,722.24
in general payments reported to CMS, 2019-2025
8 companies · $888 in 2025
The $888 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $1,024 · 2023: $1,131 · 2024: $964 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,939 · Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,939.00 |
| Food and Beverage | $1,043.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,500.08 | 2021-2024 | |
| Pfizer INC. | $726.68 | 2021-2023 | |
| Bridgebio Pharma, INC. | $608.85 | 2025 | Attruby |
| Scpharmaceuticals INC. | $443.56 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $205.43 | 2023-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Abiomed | $93.81 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.